PressAugust 18, 2022 Reunion Neuroscience Inc. Commenced Trading on the Toronto Stock Exchange August 17, 2022
PressAugust 16, 2022 Filament Health Announces Second Quarter 2022 Financial Results and Operational Highlights
PressAugust 16, 2022 Awakn Life Sciences Expands Commercial Operations into the U.S. – First Licensing Partnership Agreement with Revitalist
PressAugust 16, 2022 Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health
PressAugust 15, 2022 atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital
PressAugust 15, 2022 Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study
PressAugust 15, 2022 Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
PressAugust 15, 2022 Core One Labs’ Subsidiaries Successfully Produce Psilocin Precursor for Production to Psilocybin
PressAugust 12, 2022 Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
PressAugust 11, 2022 PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent Application
PressAugust 11, 2022 Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia
PressAugust 10, 2022 Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients
